

Advanced Breast Cancer (Partial update) GC6 – minutes

Advanced breast cancer: diagnosis and management (Partial update)

Date: 17/10/2025

Location: Virtual

Minutes: FINAL

Committee members present:		
Adam Firth	Chair	Present for notes 1 - 13
Ramsey Cutress	Breast surgeon	Present for notes 1 - 13
Mark Davies	Medical oncologist	Present for notes 1 - 13
Simon Lowes	Radiologist	Present for notes 1 - 13
Madeleine Meynell	Lay member	Present for notes 1 - 8
Mitesh Naik	Radiologist	Present for notes 1 - 13
Clare Sacco	Lay member	Present for notes 1 - 13
Elinor Sawyer	Clinical oncologist	Present for notes 1 - 13
Ben Thwaites	Pharmacist	Present for notes 1 - 13
Caroline Tweedie	Clinical Nurse Specialist	Present for notes 1 - 13

In attendance:		
Adefisayo Abba-Abba	Technical Analyst	Present for notes 1 - 13
Victoria Carter	Implementation Support Manager	Present for notes 1 - 13
Olivia Crane	Senior Technical Analyst	Present for notes 1 - 13
Gareth Haman	Senior Guidance Content Designer	Present for notes 1 - 13
Marie Harrisingh	Topic Lead	Present for notes 1 - 13
James Hawkins	Health Economics Adviser	Present for notes 1 - 13
Yolanda Martinez	Technical Analyst	Present for notes 1 - 13
Adam O'Keefe	Project Manager	Present for notes 1 - 13
Katherine Saxby	Pharmacist Clinical Adviser	Present for items 6, 11 and 12
Adam Storrow	Business Analyst, Resource Impact Assessment	Present for notes 1 - 13

NICE observers:	
Leonard Ho	Technical Analyst

Advanced Breast Cancer (Partial update) GC6 – minutes

Apologies:	
Milly Finch	Pharmacist
Karen Lockwood	Lay member
Tim Robinson	Medical oncologist
Tzujung Lai	Health Economist, NICE

1. Welcome, introductions and apologies

The Chair welcomed the committee members and NICE attendees to the sixth committee meeting for the partial update to the NICE Advanced breast cancer: diagnosis and management guideline.

The Chair informed the Committee that apologies had been received. These are noted above.

2. Declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Advanced breast cancer.

The Chair asked committee members to verbally declare any new interests, the following new interests were declared:

Name	Declaration	Date DOI arose	Action
Adam Firth	Appointment as an Ambassador for Accurx, supporting GP practices to implement a Total Triage approach.	Sep 2025	Non-specific. Declare and participate.
Simon Lowes	Received an honorarium/travel expenses from Merit Medical in relation to a presentation on breast localisation devices.	Sep 2025	Non-specific. Declare and participate.
Simon Lowes	Received an honorarium/travel expenses from Hologic in relation to delivering workshops on breast localisation devices.	Sep 2025	Non-specific. Declare and participate.

Advanced Breast Cancer (Partial update) GC6 – minutes

Simon Lowes	Received an honorarium/travel expenses from Sirius Medical in relation to delivering a workshop on breast localisation devices.	Sep 2025	Non-specific. Declare and participate.
Ben Thwaites	Support from Pfizer to attend the British Oncology Pharmacy Association Symposium in Belfast, from the 3rd to the 5th of October 2025. This covers registration for the event, travel and accommodation costs.	Oct 2025	Non-specific. Declare and participate.
Caroline Tweedie	Sponsorship for genomics work		Non-specific. Declare and participate.
Caroline Tweedie	Sponsorship from Eli Lilly as an expert on cancer related fatigue		Non-specific. Declare and participate.

The Chair and a senior member of the Developer's team noted that neither these interests nor any previously declared interests would prevent attendees from fully participating in the meeting.

3. Minutes of the previous meeting

The minutes of the previous meeting were ratified as an accurate record.

4. Review Question 2: What is the clinical and cost effectiveness of FDG PET-CT and CT with or without bone scintigraphy for the detection of distant metastases in people with suspected advanced breast cancer and does this use of FDG PET-CT improve outcomes?

Review Question 3: What is the clinical and cost effectiveness of FDG PET-CT compared to CT with or without bone scintigraphy for monitoring response to treatment and for detecting disease progression in people with advanced breast cancer?

The Chair introduced NICE Technical Analysts Adefisayo Abba-Abba and Yolanda Martinez, who reminded the committee of the clinical evidence identified in support of

Advanced Breast Cancer (Partial update) GC6 – minutes

these review questions, as resented at previous meetings.

5. Introduction to Health economics and presentation of model overview for RQ2 and RQ3

The Chair then introduced James Hawkins, Health Economics Adviser (JH) who refreshed the committee on the NICE approach to health economics and provided an overview of how the health economic model was developed.

6. Refreshing recommendations and guideline structure

The Chair introduced Marie Harrisingh, Topic Lead, who sought the committee's input on areas of the guideline undergoing a 'refresh' and the updated structure of the guideline.

7-8. Health economics results for RQ2 and RQ3 and committee discussion

JH presented the committee with results from the health economic model developed to inform the guideline update.

9-10. RQ2 and RQ3: Inequalities considerations and drafting recommendations

The committee discussed the evidence, equalities and health inequalities considerations and results of the economic modelling it had been presented with before drafting recommendations.

11. Refreshing recommendations and guideline structure

Continuation of item 6.

12. Visual summaries

The Chair introduced Katherine Saxby, Pharmacist Clinical Adviser who discussed with the committee the production of visual summaries to support the guideline.

13. AOB, Summary and next steps

Adam O'Keefe, Project Manager, outlined next steps to consultation before the Chair thanked the committee for their contributions, summarised the main actions from the day and asked for items of any other business.

The Chair then brought the meeting to a close.

Advanced Breast Cancer (Partial update) GC6 – minutes

Date of next meeting: TBC

Location of next meeting: Virtual